| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg |
| ln Vitro |
In order to stop chromosomal breakage and DNA hypomethylation, sodium folate is essential [1].
|
|---|---|
| ln Vivo |
In a mouse model of this behavior, sodium folate (10, 50, or 100 mg/kg; orally) exhibits antidepressant-like effects [2]. Mice acclimated to their new surroundings do not exhibit any psychostimulant effect from sodium folate (1, 10 nmol/site) [2]. In rat pups, oral sodium folate (1, 5 mg/kg) inhibits epigenetic changes in hepatic gene expression [3].
|
| Animal Protocol |
Animal/Disease Models: 30-40 g Swiss mice [2]
Doses: 10, 50, 100 mg/kg Route of Administration: Oral Experimental Results: diminished immobility time in forced swim test (FST) (F324=11.21), produced significant Immobility time in tail suspension test (TST) (F3,20=5.71). Animal/Disease Models: 30-40 g Swiss mice [2] Doses: 1-10 nmol/site Route of Administration: Intracerebroventricular injection Experimental Results: diminished mouse FST (F3,22=12.31) and TST (F3,22=5.50) immobile time). Animal/Disease Models: Virgin female Wistar rats [3] Doses: 1, 5 mg/kg (180 g/kg protein plus 1 mg/kg folic acid or 90 g/kg casein plus 1, 5 mg/kg folic acid) Route of Administration: Oral administration Experimental Results: Prevention of epigenetic modifications in liver gene expression in offspring. |
| References |
[1]. Butterworth CE Jr, et al. Folic acid safety and toxicity: a brief review. Am J Clin Nutr. 1989 Aug;50(2):353-8.
[2]. Brocardo PS, et al. Folic acid administration produces an antidepressant-like effect in mice: evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology. 2008 Feb;54(2):464-73. [3]. Lillycrop KA, et al. Dietary protein restriction of pregnant rats induces and folic acid supplementation prevents epigenetic modification of hepatic gene expression in the offspring. J Nutr. 2005 Jun;135(6):1382-6. [4]. Pietrzik K, et al. Folic acid and L-5-methyltetrahydrofolate: comparison of clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2010 Aug;49(8):535-48. |
| Molecular Formula |
C19H17N7O6-2.2[NA+]
|
|---|---|
| Molecular Weight |
485.36118
|
| CAS # |
6484-89-5
|
| Related CAS # |
Folic acid;59-30-3
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
[Na+].[Na+].O=C(CC[C@H](NC(C1C=CC(NCC2=CN=C3NC(=NC(=O)C3=N2)N)=CC=1)=O)C([O-])=O)[O-]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0603 mL | 10.3016 mL | 20.6033 mL | |
| 5 mM | 0.4121 mL | 2.0603 mL | 4.1207 mL | |
| 10 mM | 0.2060 mL | 1.0302 mL | 2.0603 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
